HUM

Systematic screening of Humana Inc. highlights a notable disconnect between revenue acceleration and profitability compression. The company generated revenue growth of 14.08% year-over-year, yet EPS declined 33.93% during the same period, pushing the trailing twelve-month P/E ratio to 32.14—elevated relative to the net margin of just 0.82%. This profitability squeeze appears concentrated in operational efficiency, with an operating margin of 1.73% signaling persistent cost pressures in the Medicare Advantage business model.

The fundamental screener identifies several structural strengths in Humana's positioning:

• Revenue momentum: Double-digit top-line expansion at 14.08% demonstrates sustained enrollment growth in the company's core Medicare Advantage segment, a critical metric as the demographic tailwind from aging Baby Boomers accelerates through 2030.
• Balance sheet stability: A debt-to-equity ratio of 0.7 provides financial flexibility relative to some managed care operators, though the current ratio of 0.01 reflects the sector's typical working capital structure tied to claims payables.
• Defensive characteristics: Beta of 0.74 indicates lower volatility than the broader market, consistent with healthcare's counter-cyclical demand profile.

Risk factors include the compressed ROE of 6.19% and ROA of 2.21%, both substantially below historical norms for the managed care sector. The company's price-to-book multiple of 1.74 trades at a discount to peer UNH, yet the valuation spread may reflect Medical Loss Ratio challenges and regulatory headwinds affecting Medicare reimbursement rates. The research perspective suggests monitoring quarterly MLR trends against peers ELV and CNC for comparative operational execution.